Table 1.
Demographic and speech information for a total of 296 of 320 study participants with usable speech samples and determinate Pause Marker (PM) scores.
| Group | Cohort | Title | Number of participants |
Age (years) |
% Male/% female | PCC (%) |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Samples usable for PM scores | Indeterminate PM scores | M | SD | Range | M | SD | Range | ||||
| Suspected CAS | CASI | CASI | 41 | 1 | 9.0 | 4.2 | 4–23 | 68.3/31.7 | 76.0 | 13.3 | 36.8–98.4 |
| CASN a | CASN | 19 | 1 | 10.9 | 5.2 | 4–25 | 47.4/52.6 | 75.8 | 12.3 | 44.9–92.2 | |
| Total | 60 | 2 | 9.7 | 4.6 | 4–25 | 61.7/38.3 | 76.0 | 12.9 | 36.8–98.4 | ||
| AAS | AOS | AOS | 15 | 1 | 62.3 | 11.6 | 45–82 | 73.3/26.7 | 91.6 | 7.3 | 68.9–99.4 |
| PPAOS | PPAOS | 16 | 1 | 71.0 | 9.0 | 53–84 | 56.3/43.7 | 93.0 | 6.2 | 74.0–97.9 | |
| Total | 31 | 2 | 66.8 | 11.1 | 45–84 | 64.5/35.5 | 92.3 | 6.6 | 68.9–99.4 | ||
| SD | Clinical | SD1 | 82 | 6 | 4.4 | 1.3 | 3–9 | 74.4/25.6 | 73.4 | 12.6 | 17.5–99.1 |
| Research | SD2 | 22 | 1 | 5.5 | 0.6 | 5–7 | 77.3/22.7 | 82.0 | 6.9 | 66.4–91.3 | |
| Research | SD3 | 72 | 12 | 4.0 | 0.7 | 3–5 | 73.6/26.4 | 70.0 | 9.6 | 36.2–87.2 | |
| Research | SD4 | 29 | 1 | 4.5 | 0.9 | 3–7 | 48.3/51.7 | 68.8 | 11.4 | 42.1–82.8 | |
| Total | 205 | 20 | 4.4 | 1.1 | 3–9 | 70.7/29.3 | 72.5 | 11.5 | 17.5–99.1 | ||
| Total all samples | 296 | 24 | |||||||||
Note. Speakers comprise two cohorts of participants who were suspected to have childhood apraxia of speech (CAS)—idiopathic CAS (CASI) and neurogenetic CAS (CASN); two cohorts with adult-onset apraxia of speech (AAS): apraxia of speech (AOS) and primary progressive apraxia of speech (PPAOS); and four cohort samples of participants with speech delay (SD).
PCC = percentage of consonants correct.
Includes participants with copy-number variants (n = 9) identified in related research and participants with neurodevelopmental disorders associated with disruptions in FOXP2 (n = 2), 4q;16q translocations (n = 3), 16p11.2 microdeletion syndrome (n = 2), terminal deletion of chromosome 22 (n = 1), Joubert syndrome (n = 1), and Prader–Willi syndrome (n = 1).